🔗 Share this article

Former Prime Minister Sunak has reinforced his call for a focused examination protocol for prostate cancer.

During a recent discussion, he stated being "certain of the immediate need" of establishing such a system that would be affordable, achievable and "save numerous lives".

His remarks come as the National Screening Advisory Body reviews its decision from half a decade past not to recommend regular testing.

Media reports indicate the committee may uphold its current stance.

Athlete Contributes Voice to Movement

Gold medal cyclist Chris Hoy, who has late-stage prostate cancer, supports men under 50 to be checked.

He suggests decreasing the minimum age for accessing a PSA laboratory test.

Currently, it is not automatically provided to men without symptoms who are younger than fifty.

The PSA examination remains disputed nevertheless. Measurements can rise for causes apart from cancer, such as inflammation, resulting in incorrect results.

Opponents contend this can cause unwarranted procedures and complications.

Focused Testing Initiative

The recommended examination system would focus on men aged 45–69 with a family history of prostate gland cancer and African-Caribbean males, who face twice the likelihood.

This group comprises around 1.3 million males in the UK.

Charity estimates propose the initiative would require twenty-five million pounds a year - or about eighteen pounds per participant - comparable to colorectal and mammary cancer examination.

The projection involves 20% of qualified individuals would be notified yearly, with a seventy-two percent response rate.

Medical testing (scans and tissue samples) would need to expand by twenty-three percent, with only a moderate growth in NHS staffing, based on the report.

Clinical Professionals Reaction

Some clinical specialists are sceptical about the value of screening.

They argue there is still a possibility that individuals will be medically managed for the cancer when it is not absolutely required and will then have to live with side effects such as incontinence and sexual performance issues.

One respected urological specialist remarked that "The problem is we can often detect disease that doesn't need to be addressed and we potentially create harm...and my worry at the moment is that harm to benefit ratio requires refinement."

Patient Experiences

Patient voices are also affecting the conversation.

One example concerns a 66-year-old who, after seeking a blood examination, was identified with the condition at the time of fifty-nine and was told it had progressed to his pelvic area.

He has since received chemotherapy, radiation treatment and endocrine treatment but is not curable.

The patient endorses testing for those who are potentially vulnerable.

"That is essential to me because of my boys – they are 38 and 40 – I want them tested as soon as possible. If I had been screened at fifty I am sure I would not be in the position I am currently," he said.

Future Steps

The Medical Screening Authority will have to weigh up the information and viewpoints.

Although the latest analysis suggests the consequences for personnel and capacity of a examination system would be feasible, others have contended that it would divert diagnostic capabilities from individuals being treated for other conditions.

The current discussion highlights the complicated equilibrium between early detection and likely overtreatment in prostate gland cancer treatment.